These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28055963)

  • 41. Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy.
    Foxall R; Narang P; Glaysher B; Hub E; Teal E; Coles MC; Ashton-Key M; Beers SA; Cragg MS
    Front Immunol; 2020; 11():605231. PubMed ID: 33628205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Semi-quantitative fluorescence in situ hybridization analysis indicates that the myc protein is consistently stabilized both before and after transformation of low-grade follicular center to high-grade diffuse large cell lymphoma.
    Albalwi M; Hammond DW; Goepel JR; Hough RE; Goyns MH
    Lab Invest; 1999 Jun; 79(6):707-15. PubMed ID: 10378513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.
    Wang WF; Yan L; Liu Z; Liu LX; Lin J; Liu ZY; Chen XP; Zhang W; Xu ZZ; Shi T; Li JM; Zhao YL; Meng G; Xia Y; Li JY; Zhu J
    Nat Commun; 2017 Aug; 8(1):363. PubMed ID: 28842558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
    Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
    J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.
    Kluk MJ; Ho C; Yu H; Chen BJ; Neuberg DS; Dal Cin P; Woda BA; Pinkus GS; Rodig SJ
    Am J Clin Pathol; 2016 Feb; 145(2):166-79. PubMed ID: 26834124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
    Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
    J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
    Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
    Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary cardiac diffuse large B-cell lymphoma in immunocompetent patients: clinical, histologic, immunophenotypic, and genotypic features of 3 cases.
    Soon G; Ow GW; Chan HL; Ng SB; Wang S
    Ann Diagn Pathol; 2016 Oct; 24():40-6. PubMed ID: 27649953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells.
    Sugimoto K; Hayakawa F; Shimada S; Morishita T; Shimada K; Katakai T; Tomita A; Kiyoi H; Naoe T
    Sci Rep; 2015 Aug; 5():13054. PubMed ID: 26278963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.
    Xiong J; Wang L; Fei XC; Jiang XF; Zheng Z; Zhao Y; Wang CF; Li B; Chen SJ; Janin A; Gale RP; Zhao WL
    Blood Cancer J; 2017 Jul; 7(7):e0. PubMed ID: 28686226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo.
    Nishimori T; Higuchi T; Hashida Y; Ujihara T; Taniguchi A; Ogasawara F; Kitamura N; Murakami I; Kojima K; Daibata M
    Cancer Med; 2021 Dec; 10(24):8976-8987. PubMed ID: 34821060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Highly Tumorigenic Diffuse Large B Cell Lymphoma Cells Are Produced by Coculture with Stromal Cells.
    Lin Z; Chen B; Wu T; Xu X
    Acta Haematol; 2018; 139(4):201-216. PubMed ID: 29791894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.
    D'Andrea A; Gritti I; Nicoli P; Giorgio M; Doni M; Conti A; Bianchi V; Casoli L; Sabò A; Mironov A; Beznoussenko GV; Amati B
    Oncotarget; 2016 Nov; 7(45):72415-72430. PubMed ID: 27635472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.
    Mrdenovic S; Zhang Y; Wang R; Yin L; Chu GC; Yin L; Lewis M; Heffer M; Zhau HE; Chung LWK
    Cancer; 2019 Jul; 125(13):2222-2232. PubMed ID: 30840322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network.
    Painter D; Barrans S; Lacy S; Smith A; Crouch S; Westhead D; Sha C; Patmore R; Tooze R; Burton C; Roman E
    Br J Haematol; 2019 May; 185(4):781-784. PubMed ID: 30408148
    [No Abstract]   [Full Text] [Related]  

  • 60. Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.
    Calvo-Vidal MN; Zamponi N; Krumsiek J; Stockslager MA; Revuelta MV; Phillip JM; Marullo R; Tikhonova E; Kotlov N; Patel J; Yang SN; Yang L; Taldone T; Thieblemont C; Leonard JP; Martin P; Inghirami G; Chiosis G; Manalis SR; Cerchietti L
    Cancer Res; 2021 Oct; 81(20):5202-5216. PubMed ID: 34479963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.